Has Ighel Vegue received payments from drug or device companies?

Yes. Drug and device makers reported $14,398 in general payments to Ighel Vegue across 652 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ighel Vegue did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ighel Vegue come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ighel Vegue

Family Medicine · Miami, FLNPI 1205287927

Payments from drug & device makers

$14,398in general payments, 2019–2025

Across 652 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$2K
Lilly USA, LLC$1K
AbbVie$1K
Novo Nordisk$1K
Boehringer Ingelheim$976
Mannkind Corporation$946
plus $7K from 37 others

What the payments were for

Food & beverage$14,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	63	$1,533
Lilly USA, LLC	74	$1,371
AbbVie	75	$1,142
Novo Nordisk	43	$1,046
Boehringer Ingelheim	46	$976
Mannkind Corporation	39	$946
Amgen(2 entities)	52	$941
Corcept Therapeutics	34	$716
AstraZeneca(2 entities)	21	$628
Xeris Pharmaceuticals, Inc.	25	$550
Insulet Corporation	16	$477
Zealand Pharma US, Inc.	18	$447
Esperion Therapeutics, Inc.	13	$393
Dexcom, Inc.	18	$336
Tandem Diabetes Care, Inc.	7	$285
Ascendis Pharma Endocrinology Inc	5	$207
Lifescan, Inc.	10	$176
Amarin Pharma, Inc.	4	$171
Novartis	9	$165
Radius Health, Inc.	9	$162
Amneal Pharmaceuticals LLC	8	$151
Clarus Therapeutics Inc.	2	$139
Kyowa Kirin, Inc.	7	$138
Viiv Healthcare Company	1	$118
Cequr Corporation	1	$118
Pfizer	6	$115
Ultragenyx Pharmaceutical Inc.	4	$112
BD	6	$111
Intuity Medical Inc	2	$101
Bayer	4	$85
Sequel Med Tech, LLC	4	$85
Abbott	4	$73
Antares Pharma, Inc.	4	$71
IBSA Pharma Inc.	5	$70
Recordati_rare_diseases_inc.	3	$55
Shire North American Group Inc	2	$37
Embecta Corp.	2	$33
Amphastar Pharmaceuticals, Inc.	1	$25
Merck	1	$21
Ionis Pharmaceuticals, Inc.	1	$21
Biogen	1	$20
Cardinal Health 414 LLC	1	$18
Roche Diabetes Care, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,398 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Other family medicine in Miami

Keila HooverMiami$33.7M
Jorge CasoMiami$22.6M
David WyattMiami$13.7M
Jose CardenasMiami$13.2M
Lazaro GarciaMiami$10.3M
Ibrahim Menendez PerezMiami$8.9M
Aniel Navarro MarinMiami$7.3M
Gilberto SecoMiami$6.8M
Ramon LeonMiami$6.3M
Eddy CapoteMiami$6.2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →